Vertex Pharmaceuticals Incorporated announced results from a Phase 4 open-label, multicenter, single-arm study evaluating JOURNAVX (suzetrigine) as part of multimodal therapy for moderate-to-severe acute postoperative pain following aesthetic and reconstructive plastic surgery. In the study of 99 patients, 90.7% rated treatment effectiveness as excellent, very good, or good on the Patient Global Assessment at end of treatment, and 90.9% did not require rescue opioids through up to 14 days of treatment. Vertex said the data will be presented in the future at the American Academy of Pain Medicine PainConnect 2026 meeting on March 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260305209438) on March 05, 2026, and is solely responsible for the information contained therein.